ImmunoGen, Inc.
IMGN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1,258 | $1,530 | $1,136 | $758 |
| - Cash | $275 | $275 | $294 | $176 |
| + Debt | $15 | $15 | $24 | $27 |
| Enterprise Value | $998 | $1,270 | $866 | $608 |
| Revenue | $109 | $70 | $132 | $82 |
| % Growth | 55.7% | -47.2% | 60.8% | – |
| Gross Profit | $109 | $70 | $18 | -$32 |
| % Margin | 99.8% | 100% | 13.4% | -39.2% |
| EBITDA | -$216 | -$124 | -$20 | -$66 |
| % Margin | -198.3% | -177.8% | -14.9% | -79.9% |
| Net Income | -$223 | -$139 | -$67 | -$122 |
| % Margin | -204.9% | -199.4% | -50.4% | -148.4% |
| EPS Diluted | -0.879 | -1.081 | -0.38 | -0.82 |
| % Growth | 18.7% | -184.6% | 53.7% | – |
| Operating Cash Flow | -$230 | -$230 | -$79 | -$88 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$3 |
| Free Cash Flow | -$231 | -$231 | -$80 | -$91 |